TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24189232

Group type: EXPERIMENTAL
Intervention: Variance refinement functionality in Phaser
Number of subjects: 21000

Group type: EXPERIMENTAL
Intervention: New estimate of the r.m.s.d. using sequence identity and protein size
Number of subjects: 21000

Group type: EXPERIMENTAL
Intervention: Perturbing the initial estimate of the r.m.s.d.
Number of subjects: 21000
Study: 21189110

Group type: EXPERIMENTAL
Intervention: Metal-on-metal hip arthroplasty (n = 41)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Metal-on-polyethylene hip arthroplasty (n = 44)
Number of subjects: 85
Study: 19151303

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) group received 500 mL of saline plus 500 mL of 6% HES 130/0.4
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline group received 500 mL saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received no intravascular volume preload
Number of subjects: 60
Study: 16864812

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) defined by a glomerular filtration rate < or =60 mL/minute/1.73 m2
Number of subjects: 6685

Group type: EXPERIMENTAL
Intervention: Increment of 1 SD in GFR
Number of subjects: 6685
Study: 15669380

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen treatment at 0.01 mg active ingredient/liter
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (residual house spraying with lambdacyhalothrin)
Number of subjects: 12
Study: 10958143

Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9129861

Group type: EXPERIMENTAL
Intervention: Vaccines for the common cold
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8456759

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day, increased to 40 and 80 mg/day at weeks 6 and 12
Number of subjects: 672

Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day, increased to 20 and 40 mg/day at weeks 6 and 12
Number of subjects: 672
Study: 3533672

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29275856

Group type: EXPERIMENTAL
Intervention: 64mg/day MIN-101
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 32mg/day MIN-101
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 27486051

Group type: EXPERIMENTAL
Intervention: Cognitive patient education intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study: 25590188

Group type: EXPERIMENTAL
Intervention: Wing-shaped plastic stent
Number of subjects: 37

Group type: COMPARATOR
Intervention: Self-expandable metal stent (SEMS)
Number of subjects: 37
Study: 23886644

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 1.2g daily for 24 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both treatment and placebo arms combined
Number of subjects: 14
Study: 20521985

Group type: EXPERIMENTAL
Intervention: Pressurized whey supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (casein)
Number of subjects: 22
Study: 19032398

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG) tubes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nasogastric tubes (NGT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both PEG and NGT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PEG tubes
Number of subjects: 33
Study: 16453076

Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Mesh-Plug technique
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS) technique
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 551
Study: 12717484

Group type: EXPERIMENTAL
Intervention: Molsidomine (8 mg tid)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 10764316

Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor zileuton
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 18
Study: 9034259

Group type: EXPERIMENTAL
Intervention: Intravenous human albumin (25 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous human albumin
Number of subjects: 36
Study: 8287667

Group type: EXPERIMENTAL
Intervention: Aspirated oedema fluid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Wick fluid from oedematous arm
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wick fluid from non-swollen arm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aspirate protein concentration to serum protein concentration ratio
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum protein concentration in oedema patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Serum albumin concentration in oedema patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oedema patients receiving tamoxifen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan concentration in oedema fluid
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Viscosity of oedema fluid
Number of subjects: 39
Study: 2881799

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 18
Study: 31425752

Group type: EXPERIMENTAL
Intervention: omega-3 supplements (3000 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo (refined olive oil)
Number of subjects: 43
Study: 30178092

Group type: EXPERIMENTAL
Intervention: Noradrenaline (Group A, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Terlipressin (Group B, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Noradrenaline/Terlipressin
Number of subjects: 60
Study: 28143522

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Standard-dose aspirin (325 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 24417614

Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 46

Group type: COMPARATOR
Intervention: Zirconia abutments
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both titanium and zirconia abutments
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 46
Study: 23070723

Group type: EXPERIMENTAL
Intervention: New RSA method for wear measurements without previous radiographs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional RSA method for wear measurements
Number of subjects: 27
Study: 20650376

Group type: EXPERIMENTAL
Intervention: Orbicularis oris group (n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 36
Study: 18258794

Group type: EXPERIMENTAL
Intervention: 0.15 M hydrochloric acid (HCl) infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.075 M hydrochloric acid (HCl) infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.01 M hydrochloric acid (HCl) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study: 16633299

Group type: EXPERIMENTAL
Intervention: Oxaliplatin/infusional 5-FU combination (OXFU)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxaliplatin alone (OXA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Infusional 5-fluorouracil alone (5-FU)
Number of subjects: 32
Study: 14761117

Group type: COMPARATOR
Intervention: Gm (23-) allotype in patients with chronic periodontitis (CP)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: R131 allele of the FcgammaR IIa polymorphisms in generalized aggressive periodontitis (G-AP)
Number of subjects: 154
Study: 12791218

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU every 4 months for 5 years)
Number of subjects: 0
Study: 10353936

Group type: EXPERIMENTAL
Intervention: Engerix-B vaccine administered at 0-, 1-, and 6-month intervals
Number of subjects: 389

Group type: COMPARATOR
Intervention: Engerix-B vaccine administered at 0-, 12-, and 24-month intervals
Number of subjects: 389
Study: 7564859

Group type: EXPERIMENTAL
Intervention: Combined monochromatic light/laser irradiation at low intensity (660‐950 nm; 31.9 J/cm2; pulsed at 16 Hz)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined monochromatic light/laser irradiation at low intensity (660‐950 nm; 31.9 J/cm2; pulsed at 73 Hz)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo condition (sham irradiation)
Number of subjects: 45
Study: 2014931

Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bambuterol 5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bambuterol 10 mg
Number of subjects: 20
Study: 6213349

Group type: EXPERIMENTAL
Intervention: 0.5 gm/kg ethanol followed in 1 hr by 1.0 gm IV moxalactam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 gm IV moxalactam every 8 hr for four doses followed by 0.5 gm/kg ethanol
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5 gm/kg ethanol
Number of subjects: 10
Study: 4012378

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 60
Study: 30089447

Group type: EXPERIMENTAL
Intervention: Gain-framed message reminder letter
Number of subjects: 360

Group type: COMPARATOR
Intervention: Routine reminder letter
Number of subjects: 360
Study: 27178746

Group type: EXPERIMENTAL
Intervention: Corrective advertisements with different levels of visual similarity and exposure time delay
Number of subjects: 6454

Group type: EXPERIMENTAL
Intervention: Corrective advertisements with greater time delay
Number of subjects: 6454

Group type: COMPARATOR
Intervention: Violative advertisements
Number of subjects: 6454
Study: 26088580

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy (CBT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 214
Study: 23625456

Group type: EXPERIMENTAL
Intervention: PATHS curriculum
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 14
Study: 20178064

Group type: EXPERIMENTAL
Intervention: Exercise in water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Exercise on land
Number of subjects: 17
Study: 18509580

Group type: EXPERIMENTAL
Intervention: Deep heating plus stretching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Superficial heating plus stretching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretching alone
Number of subjects: 30
Study: 17162414

Group type: EXPERIMENTAL
Intervention: Study pad (formed film top sheet)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Reference pad (leading nonwoven product)
Number of subjects: 289
Study: 14520144

Group type: COMPARATOR
Intervention: Linezolid (outpatient trial)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cefadroxil (outpatient trial)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Linezolid (inpatient trial)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vancomycin (inpatient trial)
Number of subjects: 35
Study: 11155462

Group type: EXPERIMENTAL
Intervention: UDCA 300 mg b.i.d. for twelve months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9100711

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8469914

Group type: EXPERIMENTAL
Intervention: atenolol 50/100 mg od
Number of subjects: 100

Group type: COMPARATOR
Intervention: hydrochlorothiazide 25/50 mg + amiloride 5 mg od (co-amiloride)
Number of subjects: 100
Study: 3512620

Group type: EXPERIMENTAL
Intervention: Transdermal electrical nerve stimulation (TENS)
Number of subjects: 22
Study: 26954313

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 24487961

Group type: EXPERIMENTAL
Intervention: EMD640744 (30, 100, and 300 μg doses)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EMD640744
Number of subjects: 49
Study: 22855141

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus capecitabine and radiotherapy (RT)
Number of subjects: 46
Study: 20728671

Group type: EXPERIMENTAL
Intervention: Alcohol group assessments
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Drugs group assessments
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group assessments (normal driving conditions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Parents' driving-skills assessments
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Male respondents' self-assessment
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Female respondents' self-assessment
Number of subjects: 135
Study: 18988286

Group type: EXPERIMENTAL
Intervention: 3 courses of VABEM (vindesine 5 mg/m², doxorubicin 99 mg/m², carmustine 140 mg/m², etoposide 600 mg/m², methylprednisolone 600 mg/m²) followed by low-dose lymph node irradiation
Number of subjects: 158

Group type: COMPARATOR
Intervention: 4 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by myeloablative chemotherapy with carmustine 300 mg/m², etoposide 800 mg/m², cytarabine 1600 mg/m², melphalan 140 mg/m² and autologous stem cell transplantation
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 3 courses of VABEM
Number of subjects: 158

Group type: COMPARATOR
Intervention: 4 cycles of ABVD
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 5-year FFTF rate for Arm V
Number of subjects: 158

Group type: COMPARATOR
Intervention: 5-year FFTF rate for Arm A
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 5-year overall survival rate for Arm V
Number of subjects: 158

Group type: COMPARATOR
Intervention: 5-year overall survival rate for Arm A
Number of subjects: 158
Study: 16896509

Group type: EXPERIMENTAL
Intervention: 19-week exercise program
Number of subjects: 0
Study: 12792504

Group type: EXPERIMENTAL
Intervention: CsA reduction by 50% over a 2 month period
Number of subjects: 64

Group type: COMPARATOR
Intervention: Stable-maintenance CsA dose (control group)
Number of subjects: 64
Study: 10937426

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 36
Study: 9361371

Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plain aspirin 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1364978

Group type: EXPERIMENTAL
Intervention: ACTH (Synacthen) treatment
Number of subjects: 0
Study: 4093902

Group type: EXPERIMENTAL
Intervention: Breast self-examination teaching materials (leaflet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast self-examination teaching materials (tape/slide programme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of leaflet and tape/slide programme
Number of subjects: 0
Study: 31446803

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug classes (6 classes)
Number of subjects: 4253

Group type: EXPERIMENTAL
Intervention: Factor 1 (BP pulsatility)
Number of subjects: 4253

Group type: EXPERIMENTAL
Intervention: Factor 3 (wave reflection)
Number of subjects: 4253

Group type: EXPERIMENTAL
Intervention: Factor 2 (mean BP)
Number of subjects: 4253
Study: 28784096

Group type: EXPERIMENTAL
Intervention: Knowledge and skills training for mental health professionals about DVA, knowledge and skills training of DVA professionals about mental illness, provision and implementation of a referral pathway between community mental health and DVA services
Number of subjects: 24

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 24
Study: 23969355

Group type: EXPERIMENTAL
Intervention: First Impression (FI) condition
Number of subjects: 393

Group type: COMPARATOR
Intervention: Directed Search (DS) condition
Number of subjects: 393
Study: 18356835

Group type: EXPERIMENTAL
Intervention: Self-help (SH) weight loss program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Therapist-assisted self-help (TASH) weight loss program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group-based behavioral weight loss program (BWLP)
Number of subjects: 54
Study: 16418281

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemically pure (‐)‐epicatechin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic intake of high-flavanol diets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavanol mixture resembling cocoa ingestion profile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhibition of NO synthase
Number of subjects: 0
Study: 12731635

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane-alfentanil
Number of subjects: 60
Study: 10896910

Group type: EXPERIMENTAL
Intervention: Growth hormone with glutamine (mean 0.12 mg/kg/day and oral mean 28 g/day and parenteral mean 5.2 g/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8826545

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1575821

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 9
Study: 3908674

Group type: EXPERIMENTAL
Intervention: High-feedback ultrasonography
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-feedback ultrasonography
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring
Number of subjects: 37

Group type: COMPARATOR
Intervention: Video control
Number of subjects: 37
Study: 30066623

Group type: EXPERIMENTAL
Intervention: Understanding the concept of brain death
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Not understanding the concept of brain death
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Believing brain death does not mean a person’s death
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Positive attitude toward organ donation
Number of subjects: 1524
Study: 30040791

Group type: EXPERIMENTAL
Intervention: Integrated 125I seed stents (Test group, n = 13)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional metal stents (Control group, n = 19)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Integrated 125I seed stents (Test group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional metal stents (Control group)
Number of subjects: 32
Study: 26888433

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention consisting of 50-minute center-based exercise 2× weekly, augmented with home-based activity to achieve a goal of 150 min/wk of PA
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education intervention consisting of weekly workshops for 26 weeks, and monthly sessions thereafter
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635
Study: 25125215

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (70 μg daily for 3 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22355401

Group type: EXPERIMENTAL
Intervention: 1-hour secondhand smoke (SHS) exposure at bar/restaurant carbon monoxide levels
Number of subjects: 16
Study: 19642060

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 14
Study: 17446643

Group type: EXPERIMENTAL
Intervention: Case-based e-learning
Number of subjects: 96

Group type: COMPARATOR
Intervention: Structured tutorial
Number of subjects: 96
Study: 15157037

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9620900

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) inhalation (7 +/- 1 ppm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerosolized prostaglandin E1 (PGE1) inhalation (10 +/- 1 ng/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infusion of PGE1 (12 +/- 1 ng/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study: 9012724

Group type: EXPERIMENTAL
Intervention: Mammography as a diagnostic test for women in their 40s with clinical signs requiring follow-up.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mammography for women aged 40-49.
Number of subjects: 0
Study: 1774431

Group type: EXPERIMENTAL
Intervention: 5-HT uptake inhibitors (amitriptyline, clovoxamine, fluvoxamine) for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with trazodone or maprotiline (weak inhibitors of platelet 5-HT uptake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7018317

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration after lumbar laminectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 0
Study: 31996119

Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo splint
Number of subjects: 15

Group type: COMPARATOR
Intervention: No splint
Number of subjects: 15
Study: 31665578

Group type: EXPERIMENTAL
Intervention: Gilteritinib (120 mg per day)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 371
Study: 29186198

Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 23478060

Group type: EXPERIMENTAL
Intervention: R-BEAM (rituximab 375 mg/m² on days -19 and -12, plus carmustine 300 mg/m², etoposide 100 mg/m² twice daily, cytarabine 100 mg/m² twice daily, and melphalan 140 mg/m²)
Number of subjects: 224

Group type: COMPARATOR
Intervention: B-BEAM (iodine-131 tositumomab dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -12, plus carmustine 300 mg/m², etoposide 100 mg/m² twice daily, cytarabine 100 mg/m² twice daily, and melphalan 140 mg/m²)
Number of subjects: 224